(VIANEWS) – Eagle Point Credit Company (ECC), First Financial Bankshares (FFIN), BioMarin Pharmaceutical (BMRN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Eagle Point Credit Company (ECC)
28.9% sales growth and 16.45% return on equity
Eagle Point Credit Company Inc. is a closed ended fund launched and managed by Eagle Point Credit Management LLC. It invests in fixed income markets of the United States. The fund invests equity and junior debt tranches of collateralized loan obligations consisting primarily of below investment grade U.S. senior secured loans. Eagle Point Credit Company Inc. was formed on March 24, 2014 and is domiciled in the United States.
Earnings Per Share
As for profitability, Eagle Point Credit Company has a trailing twelve months EPS of $1.74.
PE Ratio
Eagle Point Credit Company has a trailing twelve months price to earnings ratio of 5.67. Meaning, the purchaser of the share is investing $5.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.45%.
2. First Financial Bankshares (FFIN)
21.2% sales growth and 13.96% return on equity
First Financial Bankshares, Inc., through its subsidiaries, provides commercial banking products and services in Texas. The company accepts checking, savings and money market accounts, and time deposits; commercial and industrial, municipal, agricultural, construction and development, farm, non-owner occupied and owner-occupied commercial real estate, residential, and consumer auto and non-auto loans to businesses, professional individuals, and farm and ranch operations. It also provides drive-in and night deposit, remote deposit capture, internet and mobile banking, payroll cards, transmitting funds, and other customary commercial banking services, as well as automated teller machines and safe deposit facilities. In addition, the company offers personal trust services, including wealth management, administration of estates, testamentary trusts, revocable and irrevocable trusts, and agency accounts; and securities brokerage services, as well as administer retirements and employee benefits accounts, such as 401(k) profit-sharing plans and IRAs. Further, the company provides asset management and technology services. As of December 31, 2021, it had 78 financial centers across Texas. First Financial Bankshares, Inc. was founded in 1890 and is headquartered in Abilene, Texas.
Earnings Per Share
As for profitability, First Financial Bankshares has a trailing twelve months EPS of $1.41.
PE Ratio
First Financial Bankshares has a trailing twelve months price to earnings ratio of 27.99. Meaning, the purchaser of the share is investing $27.99 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.96%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 14, 2024, the estimated forward annual dividend rate is 0.72 and the estimated forward annual dividend yield is 1.87%.
Moving Average
First Financial Bankshares’s value is way higher than its 50-day moving average of $30.71 and way above its 200-day moving average of $29.54.
Volume
Today’s last reported volume for First Financial Bankshares is 905125 which is 39.22% above its average volume of 650103.
3. BioMarin Pharmaceutical (BMRN)
14.1% sales growth and 5.1% return on equity
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Earnings Per Share
As for profitability, BioMarin Pharmaceutical has a trailing twelve months EPS of $1.32.
PE Ratio
BioMarin Pharmaceutical has a trailing twelve months price to earnings ratio of 67.15. Meaning, the purchaser of the share is investing $67.15 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.1%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 19.6%, now sitting on 2.59B for the twelve trailing months.
Sales Growth
BioMarin Pharmaceutical’s sales growth is 15.6% for the present quarter and 14.1% for the next.
Volume
Today’s last reported volume for BioMarin Pharmaceutical is 1364070 which is 45.5% below its average volume of 2502930.
4. Fabrinet Ordinary Shares (FN)
13.7% sales growth and 17.79% return on equity
Fabrinet provides optical packaging and precision optical, electro-mechanical, and electronic manufacturing services in North America, the Asia-Pacific, and Europe. The company offers a range of advanced optical and electro-mechanical capabilities in the manufacturing process, including process design and engineering, supply chain management, manufacturing, printed circuit board assembly, advanced packaging, integration, final assembly, and testing. Its products include switching products, including reconfigurable optical add-drop multiplexers, optical amplifiers, modulators, and other optical components and modules that enable network managers to route voice, video, and data communications traffic through fiber optic cables at various wavelengths, speeds, and over various distances. The company's products also comprise tunable lasers, transceivers, and transponders; and active optical cables, which provide high-speed interconnect capabilities for data centers and computing clusters, as well as Infiniband, Ethernet, fiber channel, and optical backplane connectivity. In addition, it provides solid state, diode-pumped, gas, and fiber lasers used in semiconductor processing, biotechnology and medical device, metrology, and material processing industries; and differential pressure, micro-gyro, fuel, and other sensors used in automobiles, as well as non-contact temperature measurement sensors for the medical industry. Further, the company designs and fabricates application-specific crystals, lenses, prisms, mirrors, laser components, and substrates; and other custom and standard borosilicate, clear fused quartz, and synthetic fused silica glass products. It serves original equipment manufacturers of optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company was incorporated in 1999 and is based in George Town, the Cayman Islands.
Earnings Per Share
As for profitability, Fabrinet Ordinary Shares has a trailing twelve months EPS of $7.54.
PE Ratio
Fabrinet Ordinary Shares has a trailing twelve months price to earnings ratio of 25.71. Meaning, the purchaser of the share is investing $25.71 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.79%.
Sales Growth
Fabrinet Ordinary Shares’s sales growth is 11.6% for the present quarter and 13.7% for the next.
Yearly Top and Bottom Value
Fabrinet Ordinary Shares’s stock is valued at $193.84 at 01:22 EST, way under its 52-week high of $266.39 and way higher than its 52-week low of $114.83.
5. Assurant (AIZ)
8.4% sales growth and 16.43% return on equity
Assurant, Inc., together with its subsidiaries, provides lifestyle and housing solutions that support, protect, and connect consumer purchases in North America, Latin America, Europe, and the Asia Pacific. The company operates through three segments: Global Lifestyle, Global Housing, and Global Preneed. The Global Lifestyle segment provides mobile device protection products and services, and extended service contracts for consumer electronics and appliances, as well as assistance services; vehicle protection and related services; and credit and other insurance services. The Global Housing segment offers lender-placed homeowners insurance, manufactured housing, and flood insurance; and renters insurance and related products, as well as voluntary manufactured housing insurance, homeowners insurance, and other specialty products. The Global Preneed segment provides pre-funded funeral insurance, final need insurance, and related services. The company was formerly known as Fortis, Inc. and changed its name to Assurant, Inc. in February 2004. Assurant, Inc. was founded in 1892 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Assurant has a trailing twelve months EPS of $14.31.
PE Ratio
Assurant has a trailing twelve months price to earnings ratio of 11.86. Meaning, the purchaser of the share is investing $11.86 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.43%.
Volume
Today’s last reported volume for Assurant is 46166 which is 86.61% below its average volume of 344848.
